(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/034613 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/040866

(22) International Filing Date:
02 August 2024 (02.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/517,760 04 August 2023 (04.08.2023) US
63/650,658 22 May 2024 (22.05.2024) US

(71) Applicant: **TERREMOTO BIOSCIENCES, INC.** [US/US]; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US).

(72) Inventors: **CHU, Hang**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **YANG, Kin S.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **REISBERG, Solomon H.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **ZAJDLIK, Adam**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **CARELLI, Jordan D.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **BESTVATER, Brian P.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **HANSEN, Timothy R.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US). **THOMPSON, Peter A.**; 230 East Grand Avenue, 200, South San Francisco, California 94080 (US).

(74) Agent: **LESNIEWSKI, Joseph** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/034613 A1

(54) Title: 3H-IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF

(57) Abstract: Provided herein are non-covalent modifiers of AKT1 of Formula (I), (II), (II-A), (III), (III-A), (III-B), (IV), (IV-A), (IV-B), (V), (V-A), (V-B), (VI), (VI-A), or (VI-B), and pharmaceutical compositions thereof. In some embodiments, the present disclosure provides methods of modulating wild-type AKT1 using a compound or salt of Formula (I), (II), (II-A), (III), (III-A), (III-B), (IV), (IV-A), (IV-B), (V), (V-A), (V-B), (VI), (VI-A), or (VI-B), and pharmaceutical compositions thereof.